| Drug Type Gene therapy | 
| Synonyms DS-2325 | 
| Target | 
| Action inhibitors | 
| Mechanism KLK5 inhibitors(kallikrein related peptidase 5 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Netherton Syndrome | Phase 1 | United States  | 12 Oct 2022 | 





